Adaptive Biotechnologies (NASDAQ:ADPT) Insider Francis Lo Sells 22,564 Shares

Key Points

• Insider sale: Adaptive Biotechnologies insider Francis Lo sold 22,564 shares on April 8 at an average price of $15.07 for about $340,039, reducing his stake by 7.68% to 271,154 shares; the sale was executed under a pre‑arranged Rule 10b5‑1 plan and follows several large sales earlier this year.
• Mixed fundamentals and market reaction: The company beat the quarter's EPS and revenue estimates (EPS -$0.09 vs. -$0.19 est.; revenue $71.68M, +51% YoY) but remains unprofitable, and the stock traded down 4.6% to $12.79; analysts' consensus is a "Moderate Buy" with an average price target of $18.25.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 22,564 shares of the business's stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $15.07, for a total value of $340,039.48. Following the completion of the transaction, the insider owned 271,154 shares in the company, valued at $4,086,290.78. This trade represents a 7.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.08, for a total value of $430,749.44.
• On Thursday, March 5th, Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.09, for a total value of $574,536.66.
• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.73, for a total value of $1,411,130.70.

Adaptive Biotechnologies Trading Down 4.6%

NASDAQ ADPT traded down $0.61 on Friday, reaching $12.79. The stock had a trading volume of 3,310,057 shares, compared to its average volume of 2,060,273. The business has a 50 day moving average price of $15.07 and a 200 day moving average price of $15.96. Adaptive Biotechnologies Corporation has a 1 year low of $6.77 and a 1 year high of $20.76. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -31.97 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The business's quarterly revenue was up 51.0% compared to the same quarter last year. On average, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth about $28,000. Sound Income Strategies LLC acquired a new position in shares of Adaptive Biotechnologies during the 3rd quarter worth about $30,000. EverSource Wealth Advisors LLC lifted its position in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. lifted its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth about $51,000. Institutional investors and hedge funds own 99.17% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wall Street Zen downgraded Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. BTIG Research boosted their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. TD Cowen reaffirmed a "buy" rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Finally, Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of "Moderate Buy" and an average price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.